• Why a Holistic Approach May Drastically Change the Way Experiments Are Conducted

    Bio-IT World | The rush to digitalization has been underway for some time, but there is one industry that remains stuck in the past: the life sciences. While there have been numerous advancements in the way drugs are developed, lab work continues to be dominated by out-of-date processes. Improving them isn’t going to move the dial. While they may help, they are not capable of producing the level of innovation that’s needed to take us to the next phase.

    Dec 16, 2022

  • Insilico Medicine’s AI-Driven Platform Pushes The Envelope Of Drug Discovery

    Bio-IT World | During a recent virtual unveiling party livestreamed from around the world, Insilico Medicine introduced the latest updates to Pharma.AI, its end-to-end drug discovery platform using generative artificial intelligence to discover new targets, design new molecules, and predict the outcome of clinical trials. Among the highlights were the addition of a knowledge graph to target discovery product PandaOmics and numerous new panels to generative chemistry engine Chemistry42.

    Dec 15, 2022

  • Insilico Medicine’s AI-Driven Platform Pushes The Envelope Of Drug Discovery

    Bio-IT World | During a recent virtual unveiling party livestreamed from around the world, Insilico Medicine introduced the latest updates to Pharma.AI, its end-to-end drug discovery platform using generative artificial intelligence to discover new targets, design new molecules, and predict the outcome of clinical trials. Among the highlights were the addition of a knowledge graph to target discovery product PandaOmics and numerous new panels to generative chemistry engine Chemistry42.

    Dec 15, 2022

  • In Virtual Trials, Two Alzheimer’s Drugs Do Poor Job Of Slowing Cognitive Decline

    Bio-IT World | Researchers from Duke, Penn State, and the University of Tennessee collaboratively built a mathematical model of Alzheimer’s disease that used real, de-identified patient data to simulate health outcomes from a pair of anti-amyloid-beta drugs. Notably, the virtual (aka in silico) clinical trials employed a computational approach that provides “individualized prescriptions” based on optimal timing and dosing of treatment while minimizing possible side effects.

    Dec 14, 2022